TOBRAMYCIN FOR INJECTION 1.2 G — DIN 00533688
TOBRAMYCIN (TOBRAMYCIN SULFATE) : 1.2 G · FRESENIUS KABI CANADA LTD · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is TOBRAMYCIN FOR INJECTION?
TOBRAMYCIN FOR INJECTION 1.2 G contains TOBRAMYCIN (TOBRAMYCIN SULFATE) : 1.2 G. It is listed in the Health Canada Drug Product Database under DIN 00533688, held by FRESENIUS KABI CANADA LTD, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 03-Mar-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TOBRAMYCIN FOR INJECTION used for?
Tobramycin Injection, USP and Tobramycin for Injection, USP may be indicated for the treatment of the following infections when caused by susceptible organisms: septicemia, complicated and recurrent urinary tract infections, lower respiratory infections, serious skin and soft tissue infections including burns and peritonitis, and central nervous system infections caused by organisms resistant to antibiotics usually considered efficacious in these infections. Tobramycin is usually active against most strains of the following organisms in vitro and in clinical infections: Pseudomonas aeruginosa, Proteus sp., Escherichia coli, Klebsiella-Enterobacter-Serratia group, Citrobacter sp., Providencia sp., Staphylococci, including Staphylococcus aureus.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Tobramycin cost around the world?
Tobramycin is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| United States | acquisition | 3 | 19 |
| Saudi Arabia | public | 13 | 13 |
| Australia | ex-manufacturer | 7 | 12 |
| Bahrain | retail (max) | 9 | 10 |
| South Africa | single exit price | 9 | 10 |
| Romania | max producer price | 6 | 9 |
| Greece | producer price (ex-factory) | 8 | 8 |
| Norway | max AUP (pharmacy retail) | 7 | 7 |
| Sweden | AIP (pharmacy purchase price) | 5 | 7 |
| United Kingdom | hospital | 5 | 5 |
| United Arab Emirates | public | 4 | 4 |
| Luxembourg | reimbursement | 4 | 4 |
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 |
| Czechia | max producer price (ex-factory) | 2 | 2 |
112 pack listings across 84 brand entries and 13 price bases, refreshed 08 Sep 2026. Ranges span every Tobramycin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Tobramycin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Tobramycin, across 23 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS KABI CANADA LTD | 3 | 2 | TOBRAMYCIN FOR INJECTION, TOBRAMYCIN INJECTION | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 3 | 2 | TOBRAMYCIN INHALATION SOLUTION, TOBRAMYCIN INJECTION USP | Sourceable in Canada |
| BGP PHARMA ULC | 2 | 2 | TOBI, TOBI PODHALER | Sourceable in Canada |
| STERIMAX INC | 3 | 1 | TOBRAMYCIN FOR INJECTION USP, TOBRAMYCIN INJECTION USP | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 1 | JAMP-TOBRAMYCIN, TOBRAMYCIN INJECTION USP | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-TOBRAMYCIN | Sourceable in Canada |
| ELI LILLY CANADA INC | 6 | 0 | NEBCIN INJ 1.2GM/30ML, NEBCIN INJ 10MG/ML, NEBCIN INJ 10MG/ML (VANTAGE VIAL), NEBCIN INJ 40MG/ML, NEBCIN INJ 60MG, +1 more | No marketed DIN |
| AGILA JAMP CANADA INC | 1 | 0 | AJ-TOBRAMYCIN | No marketed DIN |
| LABORATOIRE RIVA INC. | 1 | 0 | TOBRAMYCIN INHALATION SOLUTION USP | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 1 | 0 | TOBRAMYCIN INJECTION, USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1.2 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Tobramycin Injection, USP, 10 mg / mL: 2 mL vials, packaged in cartons of 25 vials. Tobramycin Injection, USP, 40 mg / mL: 2 mL vials, packaged in cartons of 25 vials; 4 mL vials, packaged in cartons of 25 vials; 30 mL vials, packaged in cartons of 10 vials. Tobramycin for Injection, USP, 1.2 g / vial: 50 mL Pharmacy Bulk Vial, packaged in cartons of 6 vials. |
| Storage | Tobramycin for Injection, USP should be stored at controlled room temperatures below 30 °C. Tobramycin Injection, USP should be stored at controlled room temperature (15 °C to 30 °C). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Tobramycin |
|---|---|
| ATC code | J01GB01 |
| AHFS class | 08:12.02 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00533688 |
|---|---|
| DIN (unpadded, as printed on some documents) | 533688 |
| Brand name | TOBRAMYCIN FOR INJECTION |
| Generic / active ingredient | TOBRAMYCIN (TOBRAMYCIN SULFATE) : 1.2 G |
| Market authorization holder | FRESENIUS KABI CANADA LTD |
| Health Canada schedule | Prescription |
| ATC code | J01GB01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01GB |
| Current status | MARKETED |
| Status date | 03-Mar-2016 |
| Original market date | 1983-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Tobramycin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 23 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| TEVA-TOBRAMYCIN | 60 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | 02389622 |
| TOBI | 300 MG / 5 ML | SOLUTION | BGP PHARMA ULC | MARKETED | 02239630 |
| TOBI PODHALER | 28 MG | CAPSULE | BGP PHARMA ULC | MARKETED | 02365154 |
| TOBRAMYCIN INJECTION | 40 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02230640 |
| TOBRAMYCIN INJECTION USP | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02241209 |
| TOBRAMYCIN INJECTION USP | 40 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02241210 |
| TOBRAMYCIN INJECTION USP | 40 MG | SOLUTION | STERIMAX INC | MARKETED | 02502372 |
| TOBRAMYCIN INJECTION USP | 40 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02533103 |
| AJ-TOBRAMYCIN | 40 MG | LIQUID | AGILA JAMP CANADA INC | CANCELLED PRE MARKET | 02384930 |
| JAMP-TOBRAMYCIN | 40 MG | SOLUTION | JAMP PHARMA CORPORATION | CANCELLED POST MARKET | 02420287 |
2 · Same class — other molecules in ATC J01GB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tobramycin | AJ-TOBRAMYCIN · JAMP-TOBRAMYCIN · NEBCIN INJ 1.2GM/30ML · NEBCIN INJ 10MG/ML · +14 more | 23 | 9 | Yes |
| Gentamicin | CIDOMYCIN INJ 10MG/ML · CIDOMYCIN INJ 40MG/ML · CIDOMYCIN INJ PEDIATRIC 10MG · GARAMYCIN INJ 10MG/ML PEDIATRIC · +10 more | 20 | 6 | Yes |
| Amikacin | AMIKACIN SULFATE INJECTION · AMIKACIN SULFATE INJECTION USP · AMIKIN · ERFA-AMIKACIN · +1 more | 9 | 4 | Yes |
| Neomycin | MYCIFRADIN SULFATE ORAL SOLUTION · MYCIFRADIN SULFATE TABLETS 0.5 GM | 2 | 0 | Not in Canada |
| Netilmicin | NETROMYCIN INJ 100MG/ML · NETROMYCIN INJ 50MG/ML | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01G
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01GA | Streptomycin | 2 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TOBRAMYCIN FOR INJECTION called?
The same molecule, Tobramycin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Tobi | Latin | Australia, Bahrain, Norway, Sweden |
| Tobi podhaler | Latin | Australia, Czechia, Norway |
| Bramitob | Latin | Bahrain, Czechia, Norway, Sweden |
| Micro-Tobramicin | Latin | South Africa |
| TOBRACIN | Latin | Bahrain |
| TOBRAMYCIN SUN | Latin | Australia |
| TOBRAMYCIN WKT | Latin | Australia |
| Tobrasone | Latin | Norway, Sweden |
| Tofibra | Latin | Bahrain, Saudi Arabia |
| Toflacort | Latin | Norway, Sweden |
| MYDEX | Latin | South Africa |
| Nebcin | Latin | South Africa |
| OPTIDEX T | Latin | Bahrain |
| OPTIDEX-T STERILE OPHTALMIC SUSP | Latin | Saudi Arabia |
| Pfizer Australia Pty Ltd | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.